Admin touts TrumpRX success: it’s a quick fix, not real progress!
A new analysis from The New York Times, along with German outlets NDR and WDR, took a closer look at the administration’s new drug pricing platform, TrumpRx. What they found is that while some prices have come down, Americans are still paying significantly more than patients in other wealthy countries,
